| Code | CSB-RA008651MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to THN-391, targeting FGG (fibrinogen gamma chain), a critical component of the fibrinogen complex. FGG encodes the gamma polypeptide chain of fibrinogen, a soluble plasma glycoprotein essential for blood coagulation and hemostasis. Upon vascular injury, thrombin cleaves fibrinogen to form fibrin monomers that polymerize into insoluble clots, playing a fundamental role in wound healing and thrombosis. Dysregulation of FGG has been implicated in various coagulation disorders, thrombotic diseases, and cardiovascular pathologies. Additionally, aberrant fibrinogen expression and deposition have been associated with inflammatory conditions, cancer progression, and tumor microenvironment remodeling.
The reference antibody THN-391 has been utilized in research investigating fibrinogen structure, function, and pathological roles in hemostatic and thrombotic processes. This biosimilar provides researchers with a reliable tool for studying FGG-related mechanisms in coagulation biology, vascular disease models, and fibrin matrix formation. It supports investigations into hemostasis, thrombosis, inflammation, and fibrinogen-mediated cellular interactions across various experimental systems.
There are currently no reviews for this product.